Results 161 to 170 of about 1,693 (197)

[Tocolysis. Atosiban, an ocytcin-receptor antagonist].

Journal de gynecologie, obstetrique et biologie de la reproduction, 2001
Atosiban, the first member of a new tocolytic drug class, the ocytocin-receptor antagonists, has just been awarded marketing approval in Europe. The clinical effectiveness of atosiban is comparable to that of ritodrine, but atosiban is better tolerated with no evidence of significant maternal or fetal adverse effects.
T, Schmitz, D, Cabrol
openaire   +1 more source

Atosiban

Reactions Weekly, 2018
openaire   +1 more source

Atosiban and non-cardiogenic pulmonary oedema

International Journal of Obstetric Anesthesia, 2012
G A, Wright, D M, Levy
openaire   +2 more sources

Atosiban

Reactions Weekly, 2013
openaire   +1 more source

Atosiban/betamethasone

Reactions Weekly, 2018
openaire   +1 more source

Atosiban for the primary prevention of preterm labour

BJOG: An International Journal of Obstetrics & Gynaecology, 2001
T A, Johnston, A D, Cameron
openaire   +2 more sources

Atosiban/betamethasone

Reactions Weekly, 2011
openaire   +1 more source

Wehenhemmung mit Atosiban

Geburtshilfe und Frauenheilkunde, 2003
H. Helmer, P. Husslein
openaire   +1 more source

Atosiban/desmopressin

Reactions Weekly, 2017
openaire   +1 more source

Atosiban/nifedipine

Reactions Weekly, 2015
openaire   +1 more source